drugset / Trial / NCT05060796
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
NaSingle-groupOpen-labelTreatment
Summary
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2019-09-01
- Primary completion
- 2029-11-01
- Completion
- 2034-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells | Cell therapy | 1.58 cells/kg | Intravenous |
| Subject | CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells | Cell therapy | 5 cells/kg | Intravenous |